Form 4: Dyne Therapeutics CEO Joshua Brumm Sells Shares to Cover Tax Obligations

Dyne Therapeutics CEO Joshua Brumm sold 9,086 shares of common stock on March 7, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.

Summary

• On March 7, 2024, Joshua T Brumm, CEO and President of Dyne Therapeutics, Inc., sold 9,086 shares of common stock.
• The sale was executed at a weighted average price of $25.85 per share, with individual transactions ranging from $25.84 to $26.32.
• This sale was to cover tax withholding obligations related to the vesting of restricted stock units granted on November 15, 2023.
• The sale was automated under a pre-existing agreement consistent with Rule 10b5-1(c).
• Following the transaction, Brumm still beneficially owns 554,385 shares, including 530,300 unvested RSUs.

Sentiment

Score: 5

Explanation: This is a neutral event. The stock sale is related to tax obligations and doesn't necessarily reflect a change in the executive's confidence in the company.

Industry Context

This is a routine transaction related to executive compensation and tax obligations. It is common for executives to sell shares to cover taxes when restricted stock units vest.

Comparison to Industry Standards

• Executive stock sales for tax purposes are a common practice across publicly traded companies.
• The sale was conducted under a 10b5-1 plan, which is a standard method to avoid insider trading accusations.
• Comparable companies in the biotechnology sector often have similar executive compensation structures involving RSUs and subsequent stock sales for tax obligations.

Stakeholder Impact

• The sale may have a minor impact on shareholders due to the small volume of shares sold.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates